LGND Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Ligand Pharmaceuticals Inc (LGND) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock shows strong technical indicators, positive analyst sentiment, and potential catalysts from upcoming FDA approvals and revenue growth opportunities. Despite a recent drop in net income and EPS, the company's revenue growth and strong gross margin suggest long-term potential.
The technical indicators for LGND are bullish. The MACD is positively expanding, RSI is neutral at 57.866, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key resistance levels are at 208.364 and 213.471, while support levels are at 191.831 and 186.724. The pre-market price is $206.49, up 0.41%, indicating positive momentum.
Analysts have raised price targets, with Citi highlighting a potential FDA approval catalyst by April
Oppenheimer and H.C. Wainwright emphasize strong royalty revenue potential and positive Phase 3 trial results.
The company's revenue grew 39.37% YoY in Q4 2025, and gross margin improved to 81.42%.
Net income dropped significantly by -244.06% YoY in Q4 2025, and EPS fell by -232.32%.
Options data shows higher put volume compared to call volume, indicating cautious sentiment in the short term.
In Q4 2025, revenue increased by 39.37% YoY to $59.67M, and gross margin improved to 81.42%. However, net income dropped by -244.06% YoY to $44.78M, and EPS decreased by -232.32% to $2.17.
Analysts are bullish on LGND. Citi raised the price target to $276 and expects FDA approval for Travere by April 13. Oppenheimer raised the price target to $277, citing strong royalty revenue potential. H.C. Wainwright increased the price target to $239, highlighting positive Phase 3 trial results. BofA initiated coverage with a Buy rating and a $244 price target, emphasizing the company's portfolio and lean cost structure.
